Comparative risk of acute myocardial infarction for anti-osteoporosis drugs in primary care: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database

Accepted/In Press date: 3 December 2021

e-pub ahead of print date: 9 February 2022

Published date: 1 July 2022

Additional Information: Funding Information: This work was partially funded by a Project Grant from the National Osteoporosis Society. This work was supported by the NIHR Biomedical Research Centre, Oxford. DPA is funded by a National Institute for Health Research Clinician Scientist award (CS-2013–13-012). Andrew Judge was supported by the NIHR Biomedical Research Centre at the University Hospitals Bristol NHS Foundation Trust and the University of Bristol. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health. This study has been approved by the Independent Scientific Advisory Committee (ISAC, protocol number 14_110). This study is based in part on data from the Clinical Practice Research Datalink obtained under licence from the UK Medicines and Healthcare products Regulatory Agency. The data is provided by patients and collected by the NHS as part of their care and support. The interpretation and conclusions contained in this study are those of the author/s alone. Funding Information: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare Cyrus Cooper reports Personal fees from Alliance for Better Bone Health, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier, Takeda, and UCB. Kassim Javaid reports honoraria, unrestricted research grants, and travel and/or subsistence expenses from Amgen, Lilly UK, Shire, Internis, Consilient Health, Stirling Anglia Pharmaceuticals, Mereo Biopharma, Optasia Medical, Zebra Medical Vision, Kyowa Kirin Hakin, and UCB. Andrew Judge reports consultancy fees, lecture fees, and honoraria from Servier, UK Renal Registry, Oxford Craniofacial Unit, IDIAP Jordi Gol, and Freshfields Bruckhaus Deringer, is a member of the Data Safety and Monitoring Board (which involved receipt of fees) from Anthera Pharmaceuticals, Inc., and received consortium research grants from Roche. Bo Abrahamsen reports Institutional research grants UCB and Novartis. Advisory board and consulting fees UCB. Daniel Prieto Alhambra reports DPA’s institution received speaker fees from AMGEN and UCB Biopharma; consultancy fees from UCB Biopharma; research grants from UCB, Amgen, and Les Laboratoires Servier; and financial support to organise educational activities from Janssen (on behalf of IMI-funded EHDEN and EMIF consortiums) and Synapse Management Partners. Sara Khalid, Sara Calderon-Larranaga, Arvind Sami, Samuel Hawley, and Tjeerd P Van Staa declare that they have no conflict of interest.

Keywords: Acute myocardial infarction, CPRD, Osteoporosis treatment, SIDIAP

Local EPrints ID: 484563

URI: http://eprints.soton.ac.uk/id/eprint/484563

DOI: doi:10.1007/s00198-021-06262-1

ISSN: 0937-941X

PURE UUID: fdf8aa57-f8ad-4d7a-bcea-6bb1c89bf39e

ORCID for C. Cooper: orcid.org/0000-0003-3510-0709

Date deposited: 16 Nov 2023 17:48

Last modified: 16 Apr 2024 01:35